Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MTP-101C in Amyotrophic Lateral Sclerosis
NCT07017946Phase 2Recruiting
- Sponsor
- Duke University
- Start
- Jan 2026
- Primary completion
- Nov 2026
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
A Phase 2 trial of MTP-101 in amyotrophic lateral sclerosis (ALS), sponsored by Duke University. Started Jan 2026; status: recruiting.
02
Drugs
MTP-101
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT07017946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07017946.